New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
10:02 EDTKPTIKaryopharm enters into preferred provider agreement with Clinipace Worldwide
Clinipace Worldwide announced that Karyopharm Therapeutics has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. As part of a long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
08:53 EDTKPTIConcerns over Karyopharm overdone, says Wedbush
After eight AML patients taking Karyopharm's Sellinexor developed Sepisis versus two in the control arm, Wedbush quotes a doctor as saying that differences in patients' characteristics between the two arms may have contributed to the high rate of Sepsis in those taking Sellinexor,. Wedbush believes that a study of the 60 mg version of the drug, due out in 4Q16, will show that it improves survival and has an acceptable safety profile. Wedbush increased its discount rate on AML to 45% from 30% to account for higher risk from a reduced dose and cut its price target on the name to $39 from $50, mostly due to the postponement of clinical trial results. However, the firm keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use